This Article Full Text Full Text (PDF) All Versions of this Article: 92/5/1653    most recent Author Manuscript (PDF) Submit a related Letter to the Editor View responses Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Menconi, F. Articles by Marcocci, C. Search for Related Content PubMed PubMed Citation Articles by Menconi, F. Articles by Marcocci, C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Steroids Related Collections Autoimmunity Thyroid

Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves’ Orbitopathy Treated with Intravenous Glucocorticoids

Departments of Endocrinology (F.M., M.M., A.P., R.R., B.M., C.M.) and Neuroscience (M.N.), University of Pisa, 56124 Pisa, Italy; and Department of Clinical Medicine (L.B.), Section of Endocrinology, University of Insubria, 21100 Varese, Italy

Address all correspondence and requests for reprints to: Claudio Marcocci, M.D., Department of Endocrinology, University of Pisa, Via Paradisa 2, 56100 Pisa, Italy. E-mail: c.marcocci{at}endoc.med.unipi.it.

Context: Graves’ orbitopathy (GO) is probably caused by autoimmune reactions against autoantigen(s) shared by thyroid and orbital tissues sustained by intrathyroidal autoreactive T-lymphocytes infiltrating the orbit. Total thyroid ablation (TTA) may be beneficial for GO through removal of shared antigen(s) and autoreactive T-lymphocytes, but randomized studies are lacking.

Objective: Our objective was to evaluate the effects of TTA in patients with GO treated with iv glucocorticoids (GC).

Design/Setting: A prospective, single-blind, randomized study was conducted at a referral center.

Patients/Interventions: Sixty patients with mild to moderate GO were randomized into: 1) near-total thyroidectomy (TX); or 2) TX plus ¹³¹I (TTA) groups, and then treated with iv GC. Patients were evaluated 3 and 9 months after iv GC.

Main Outcome Measure: Overall improvement of GO at 9 months was the main outcome measure.

Results: The distribution of GO outcome at 9 months was significantly more favorable in TTA than in TX patients (P = 0.0014 by ² test). A cumulative significant (P = 0.0054) difference between the two groups at 3 and 9 months was found using a generalized linear model. Radioiodine uptake test and thyroglobulin assay in a patient sample showed complete ablation in the majority of TTA, but not of TX patients.

Conclusions: Compared with thyroidectomy alone, TTA is followed by a better outcome of GO in patients given iv GC. Whether TTA maintains this advantage in the long-term remains to be established.

This article has been cited by other articles:

				L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]

eLetters: